There are many therapeutic cancer vaccines designed to harness the immunological system to limit the growth or spread of cancer under investigation in early-phase clinical trials. However, the vast majority are being developed with little or no immunological monitoring to determine whether and how the human immune system is responding to the vaccine being studied. The Cancer Vaccine Collaborative (CVC), a partnership established by the Cancer Research Institute in New York and the international Ludwig Institute for Cancer Research (LICR), has announced that it is the first to demonstrate that vaccination with a cancer-specific recombinant protein antigen has successfully induced a fully integrated immunological response in humans.
Read the rest of this entry »

A vaccine that could reduce cervical cancer rates by 75 percent is safe and 95 percent effective, according to a study of 1,113 women in North America and Brazil. Read the rest of this entry »